Compare R & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | R | BLTE |
|---|---|---|
| Founded | 1933 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Rental/Leasing Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 6.5B |
| IPO Year | 1994 | 2021 |
| Metric | R | BLTE |
|---|---|---|
| Price | $190.04 | $154.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 8 |
| Target Price | ★ $214.44 | $181.14 |
| AVG Volume (30 Days) | ★ 281.8K | 163.7K |
| Earning Date | 04-22-2026 | 03-02-2026 |
| Dividend Yield | ★ 1.89% | N/A |
| EPS Growth | ★ 7.96 | N/A |
| EPS | ★ 11.94 | N/A |
| Revenue | ★ $12,665,000,000.00 | N/A |
| Revenue This Year | $3.91 | N/A |
| Revenue Next Year | $5.74 | $363.39 |
| P/E Ratio | $16.15 | ★ N/A |
| Revenue Growth | ★ 0.23 | N/A |
| 52 Week Low | $125.54 | $49.00 |
| 52 Week High | $230.39 | $200.00 |
| Indicator | R | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 37.82 | 34.46 |
| Support Level | $184.78 | $148.78 |
| Resistance Level | $197.80 | $161.28 |
| Average True Range (ATR) | 5.84 | 8.38 |
| MACD | -1.98 | -2.66 |
| Stochastic Oscillator | 17.71 | 6.16 |
Ryder System Inc operates in three business segments: (1) Fleet Management Solutions which provides full-service leasing and leasing with flexible maintenance options, commercial rental and maintenance services of trucks, tractors and trailers to customers; (2) Supply Chain Solutions (SCS), which provides integrated logistics solutions, including distribution management, dedicated transportation, transportation management, brokerage, e-commerce, last mile, and professional services; and (3) Dedicated Transportation Solutions (DTS), which provides turnkey transportation solutions in the U.S., including dedicated vehicles, professional drivers, management, and administrative support.
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.